CytomX Therapeutics, Inc.
CTMX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $6 | $19 | $51 | $38 |
| % Growth | -68% | -63.4% | 33.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $6 | $19 | $51 | $38 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $15 | $13 | $19 | $15 |
| G&A Expenses | $6 | $7 | $9 | $6 |
| SG&A Expenses | $6 | $7 | $9 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $22 | $20 | $28 | $20 |
| Operating Income | -$16 | -$1 | $23 | $18 |
| % Margin | -264.4% | -6.9% | 44.4% | 46.4% |
| Other Income/Exp. Net | $2 | $1 | $1 | $1 |
| Pre-Tax Income | -$14 | -$0 | $24 | $19 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$14 | -$0 | $24 | $19 |
| % Margin | -238.6% | -0.8% | 46.2% | 49.6% |
| EPS | -0.09 | -0.001 | 0.27 | 0.24 |
| % Growth | -7,400% | -100.4% | 12.5% | – |
| EPS Diluted | -0.09 | -0.001 | 0.27 | 0.24 |
| Weighted Avg Shares Out | 165 | 129 | 87 | 80 |
| Weighted Avg Shares Out Dil | 165 | 129 | 87 | 80 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$14 | -$1 | $23 | $18 |
| % Margin | -235.4% | -5% | 45.2% | 47.5% |